We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced that the Company presented preclinical data from a fully human CD73 antibody (HBM1007) in an e-poster at the American Association for Cancer Research (AACR) Virtual A